Back to all Programs

Past Event

Related Materials

Past Event

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Viral Hepatitis and Liver Disease

Who Should We Treat? What is the “Point-of-No-Return”? - Norah Terrault, MD, MPH, FAASLD

Viral Hepatitis and Liver Disease

Treatment Experienced GT3 patient with Cirrhosis - Geoffrey McCaughan, MD, PhD

Viral Hepatitis and Liver Disease

Is Treatment Cost-effective? - Kosh Agarwal, MD

Viral Hepatitis and Liver Disease

What Are the Treatment Options? - Xavier Forns, MD

Viral Hepatitis and Liver Disease

When to Treat HCV in a Waiting List Patient? - Stefano Fagiuoli, MD

Viral Hepatitis and Liver Disease

Achieving SVR in CTP C – MELD Purgatory - Christophe Duvoux, MD

Viral Hepatitis and Liver Disease

What Are the Treatment Options? - Maria Londoño, MD

Viral Hepatitis and Liver Disease

Use of HCV+ Donor Grafts - Didier Samuel, MD, PhD

Viral Hepatitis and Liver Disease

Post-LT Renal Failure and HCV Rx - Peter Ferenci, MD

Viral Hepatitis and Liver Disease

Obstacles to Treatment: Renal Disease, Ribavirin, DDIs - Michael Charlton, MD

Viral Hepatitis and Liver Disease

Management of DAA Failures - Gregory T. Everson, MD